GlassScriptPhysician profile
Nadyeschka Rivera
NPI 1205284114
$7,790.93
in general payments reported to CMS, 2019-2025
22 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $932 · 2021: $2,245 · 2022: $1,348 · 2023: $1,239 · 2024: $1,040 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,341 · Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,340.59 |
| Food and Beverage | $1,095.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,604.28 | 2021-2025 | Nim Vital, Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,401.85 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,113.82 | 2019-2025 | Farxiga, Lokelma |
| Sanofi-Aventis U.S. LLC | $567.00 | 2019-2022 | |
| Novo Nordisk INC | $505.94 | 2020-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $477.71 | 2021-2024 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $319.97 | 2019-2022 | |
| Amgen INC. | $287.00 | 2021 | |
| Abbott Laboratories | $251.97 | 2020-2025 | Freestyle Libre 3 |
| Pbg Puerto Rico LLC | $184.63 | 2020-2023 | |
| Dexcom, INC. | $144.73 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $140.21 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $133.06 | 2021-2022 | |
| Corcept Therapeutics | $124.92 | 2021 | |
| Abbvie INC. | $120.00 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $118.75 | 2022 | |
| Lilly USA, LLC | $118.71 | 2024 | Zepbound |
| Rhythm Pharmaceuticals, INC. | $69.83 | 2022 | |
| Radius Health, INC. | $32.83 | 2020 | |
| Novartis Pharmaceuticals Corporation | $29.09 | 2022 | |
| Insulet Corporation | $22.70 | 2022 | |
| Pfizer Pharmaceuticals LLC | $21.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadyeschka Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.